Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04591678 · ClinicalTrials.gov registry record
Adults With SMA Treated With Nusinersen
A clinical trial, sponsored by Ohio State University.
- Completed
- Registry status
- 15
- Enrollment target
NCT04591678: Completed study, sponsored by Ohio State University.
NCT04591678 is a clinical trial that has completed, run by Ohio State University. The registered enrollment target is 15 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04591678 has completed, sponsored by Ohio State University.
- COMPLETED
- Registry status
- 15 participants
- Enrollment target
Study Summary
This is a single center, 22-month observational study of nusinersen treatment in adult patients with spinal muscular atrophy (SMA). There will be a total of seven visits. Nusinersen is provided as standard of care and not considered research in this study. Information will be collected regarding the general health, and function including muscle strength of, as well as any positive and/or adverse events experienced by the study participants.
Primary Outcome
To evaluate the effect of nusinersen treatment on muscle strength in ambulatory SMA adults
Interventions
- DRUG nusinersen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2018-10-01 |
| Est. Completion | 2021-06-25 |
What the finished NCT04591678 record still lists
NCT04591678 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 15 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which nusinersen is the first listed.
NCT04591678 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04591678 about?
NCT04591678 is a clinical study titled "Adults With SMA Treated With Nusinersen". This is a single center, 22-month observational study of nusinersen treatment in adult patients with spinal muscular atrophy (SMA). There will be a total of seven visits. Nusinersen is provided as standard of care and not considered research in this study. Information will be collected regarding the...
What is the current status of trial NCT04591678?
This trial is currently completed. The enrollment target is 15 participants. The study started on 2018-10-01. Estimated completion is 2021-06-25.
What interventions are being tested in trial NCT04591678?
The interventions under investigation include: nusinersen (DRUG).
Who is sponsoring clinical trial NCT04591678?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI